CosmoFarm posts record $15m Q2 revenue on pharmacy network growth
CosmoFarm, the Greek pharmaceutical wholesale subsidiary of NASDAQ-listed Cosmos Health, reported record quarterly revenue of over $15 million for the second quarter of 2026, equivalent to an annualised run-rate of more than $60 million. The figure marks a step-change for the Athens-area distributor, which also added more than 80 pharmacies to its network during the period.
Cosmos Health chief executive Greg Siokas said the result reflected the strength of CosmoFarm's distribution platform and the trust of its expanding customer base. "By investing further in robotic automation, artificial intelligence, and expanded facility capacity, we are positioning CosmoFarm to sustain this momentum, improve margins, and continue scaling profitably," he said.
Automation and capacity investment
To support further growth, Cosmos Health is increasing capital expenditure at CosmoFarm with new robotic automation and AI systems targeting procurement, inventory management, and order fulfilment. The company is also physically expanding the CosmoFarm facility to handle higher throughput. These investments layer onto existing infrastructure that already includes ROWA and SSI SCHÄFER A-frame robotic picking systems, which the company says have already improved unit economics and profitability per customer.
The company did not provide specific capex figures, an updated pharmacy network total, or granular margin data alongside the revenue announcement. No timeline was given for when the facility expansion will be complete.
Market context
Greek pharmaceutical wholesale is a fragmented but consolidating market, dominated by a small number of regional distributors serving independent community pharmacies, which remain the primary retail channel in Greece. CosmoFarm's strategy of combining physical distribution scale with automation mirrors approaches taken by larger European wholesalers such as McKesson Europe and Alliance Healthcare, which have invested heavily in warehouse robotics to defend margins against pricing pressure from generic penetration and reimbursement reform.
Cosmos Health itself is a broader healthcare group with manufacturing through its EMA-certified Cana Laboratories subsidiary, proprietary nutraceutical brands, and a telehealth footprint via ZipDoctor in the United States.